Effect of Pilocarpine 0.2% for the Treatment of Presbyopia

Marrium  Shafi; Yaseen  Lodhi; Asma  Aftab; Haroon  Sarfraz; Muhammad Akmal  Khan; Asad Ali  Khan

doi:10.51253/pafmj.v76iSUPPL-1.12900

Authors

Marrium Shafi Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Yaseen Lodhi Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Asma Aftab Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Haroon Sarfraz Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Muhammad Akmal Khan Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Dr Asad Ali Khan Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-1.12900

Keywords:

Near vision, Presbyopia, Pilocarpine

Abstract

Objective: To determine the effect of Pilocarpine 0.2% for the treatment of presbyopia.

Study Design: Quasi-experimental Study.

Place and Duration of Study: Ophthalmology Department, POF Hospital, Wah Cantt, Pakistan from Jul to Sep 2024.

Methodology: One hundred and five patients (40–55 years) with presbyopia impacting daily activities were selected. Near vision was recorded before and after 1 hour of instillation of 0.2 % Pilocarpine drops and improvement in the number of lines in near vision was recorded. Patients were further divided into three Groups based on their age, i.e., 35 patients in each Group. Group 1 (40 to 45 years); Group 2 (46 to 50 years); and Group 3 (51 to 55 years). Improvement in near vision in each Group was also recorded.

Results: Among 105 participants, 48(46.0%) were females and 57(54.0%) were males. Topical Pilocarpine 0.2% was instilled in 105 individuals; 93 of them had an improvement in their near vision, whereas 12(11.4%) patients showed no improvement. Out of 93 patients who showed improvement, 56(53.3%) patients showed improvement of 1 line, 32(30.5%) patients showed improvement of 2 lines, and 5(4.8%) patients showed improvement of 3 lines in near vision. Improvement in near vision in each Group was also analyzed and it was statistically significant (p-value 0.024). Younger age Group showed more improvement as compared to older patients with Pilocarpine 0.2%.

Conclusion: Topical Pilocarpine 0.2% for the treatment of presbyopia is effective and has encouraging excellent results, especially in early presbyopia.

Downloads

Download data is not yet available.

Author Biography

Marrium Shafi, Department of ophthalmology, Wah Medical College, Wah Cantt/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

References

1. Zhang G, Wei Q, Lu L, Lin AL, Qu C. The evolution of mechanism of accommodation and a novel hypothesis. Graefes Arch Clin Exp Ophthalmol 2023; 261(11): 3083-3095.

https://doi.org/10.1007/s00417-023-06045-w

2. Tsuneyoshi Y, Masui S, Arai H, Toda I, Kubota M, Kubota S, et al. Determination of the standard visual criterion for diagnosing and treating presbyopia according to subjective patient symptoms. J Clin Med 2021; 10(17): 3942.

https://doi.org/10.3390/jcm10173942

3. Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis, and modelling. Ophthalmol 2018; 125(10): 1492-1499.

https://doi.org/10.1016/j.ophtha.2018.04.013

4. Abdullah AS, Jadoon MZ, Akram M, Awan ZH, Azam M, Safdar M, et al. Prevalence of uncorrected refractive errors in adults aged 30 years and above in a rural population in Pakistan. J Ayub Med Coll Abbottabad 2015; 27(1): 8-12.

5. Wolffsohn JS, Davies LN, Sheppard AL. New insights in presbyopia: impact of correction strategies. BMJ Open Ophthalmol 2023; 8(1): e001122.

https://doi.org/10.1136/bmjophth-2022-001122

6. Kim DY, Ahn H, Lee S, Jun I, Seo KY, Kim SY, et al. Efficacy of a new refractive multifocal contact lens for presbyopia. Sci Rep 2024; 14(1): 8878. https://doi.org/10.1038/s41598-024-55918-5

7. Fernández J, Molina-Martín A, Rocha-de-Lossada C, Rodríguez-Vallejo M, Piñero DP. Clinical outcomes of presbyopia correction with the latest techniques of presbyLASIK: a systematic review. Eye 2023; 37(4): 587-596.

https://doi.org/10.1038/s41433-022-02175-3

8. Brenner LF, Nistad K, Schonbeck U. Rethinking presbyopia: results of bilateral refractive lens exchange with trifocal intraocular lenses in 17 603 patients. Br J Ophthalmol 2023; 107(7): 912-919.

https://doi.org/10.1136/bjophthalmol-2021-319732

9. Jiménez-Ortiz HF, Fernández NT. Pharmacological treatments for the correction of presbyopia. Arch Soc Esp Oftalmol 2024; 99(8): 331-339. https://doi.org/10.1016/j.oftale.2024.04.008

10. Szumny D. The use of Pilocarpine in the treatment of presbyopia. OphthaTherapy 2022; 9(3): 189-193.

https://doi.org/10.24292/01.OT.300922.3

11. Zhang X, Xiong X, Zhang H, Huang T, Zhou X. Pilocarpine in the Treatment of Presbyopia: Progress, Issues, and Future Prospects. Drugs Aging 2024; 41: 897-906.

https://doi.org/10.1007/s40266-024-01155-4

12. Surachatkumtonekul T, Jutasompakorn P, Klinniyom A, Sermsripong W, Hokierti K, Sangsre P, et al. Efficacy and Safety of Pilocarpine Eye Drops Combinations for Treating Presbyopia in a Thai Population: A Randomized Crossover Trial. Siriraj Med J 2024; 76(10): 718-726.

https://doi.org/10.33192/smj.v76i10.268911

13. Vargas V, Vejarano F, Alió JL. Near vision improvement with the use of a new topical compound for presbyopia correction: a prospective, consecutive interventional non-comparative clinical study. Ophthalmol Ther 2019; (1): 31-39.

https://doi.org/10.1007/s40123-018-0154-6

14. Holland E, Karpecki P, Fingeret M, Schaeffer J, Gupta P, Fram N, et al. Efficacy and safety of CSF-1 (0.4% Pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther 2024; 46(2): 104-113.

https://doi.org/10.1016/j.clinthera.2023.12.005

15. Price Jr FW, Hom M, Moshirfar M, Evans D, Liu H, Penzner J, et al. Combinations of Pilocarpine and oxymetazoline for the pharmacological treatment of presbyopia: two randomized phase 2 studies. Ophthalmol Sci 2021; 1(4): 100065.

https://doi.org/10.1016/j.xops.2021.100065

16. Haghpanah N, Alany R. Pharmacological treatment of presbyopia: A systematic review. Eur J Transl Myol 2022; 32(3): 10781.

https://doi.org/10.4081/ejtm.2022.10781

17. Renna A, Vejarano LF, De la Cruz E, Alió JL. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: a pilot study. Ophthalmol Ther 2016; 5(1): 63-73.

https://doi.org/10.1007/s40123-016-0050-x

18. Benozzi G, Perez C, Leiro J, Facal S, Orman B. Presbyopia treatment with eye drops: an eight year retrospective study. Transl Vis Sci Technol 2020; 9(7): 25.

https://doi.org/10.1167/tvst.9.7.25

19. Orman B, Benozzi G. Pharmacological treatments for presbyopia. Drugs Aging 2023; 40(2): 105-116.

https://doi.org/10.1007/s40266-022-01002-4

20. Grzybowski A, Ruamviboonsuk V. Pharmacological treatment in presbyopia. J Clin Med 2022; 11(5): 1385.

https://doi.org/10.3390/jcm11051385

21. Waring GO, Price FW, Wirta D, McCabe C, Moshirfar M, Guo Q, et al. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol 2022; 140(4): 363-371.

https://doi.org/10.1001/jamaophthalmol.2022.0059

22. Shafer BM, McGee SR, Ifantides C, Williamson BK, Kannarr S, Whyte J, et al. Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study. Ophthalmol Ther 2024; 13: 1-20.

https://doi.org/10.1007/s40123-024-00935-w

23. Eton EA, Zhao PY, Johnson MW, Rao RC, Huvard MJ. Rhegmatogenous Retinal Detachment After Initiation Of Pilocarpine Hydrochloride Ophthalmic Solution 1.25% For Treatment Of Presbyopia. Retin Cases Brief Rep 2024; 18(1): 98-100.

https://doi.org/10.1097/icb.0000000000001309